Barclays raised the firm’s price target on BeOne Medicines (ONC) to $394 from $385 and keeps an Overweight rating on the shares as part of a Q4 earnings preview in the biotechnology group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ONC:
- Zanubrutinib Update: What BeiGene’s BTK Intolerance Study Means for Oncology Investors
- Prelude Therapeutics’ PRT2527 Trial Completion: What Investors Should Watch in Hematologic Oncology
- BeiGene’s BGB-24714 Solid Tumor Trial Terminated: What It Means for Oncology Investors
- BeOne Medicines Targets CLL Leaders With New Phase 3 Head-to-Head Trial
- BeOne Medicines upgraded to Outperform from Market Perform at Bernstein